Meeting
2022 ASCO Annual Meeting
Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).
Authors
Charlene Mantia
Dana-Farber Cancer Institute, Boston, MA
Charlene Mantia , Opeyemi Jegede , Meredith M. Regan , Michael B. Atkins , David F. McDermott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4544)
DOI
10.1200/JCO.2022.40.16_suppl.4544
Abstract #
4544
Poster Bd #
35
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
First Author: Regina Barragan-Carrillo
Poster
2023 ASCO Genitourinary Cancers Symposium
CARINA interim analysis: A non-interventional study of real-world treatment sequencing and outcomes in patients with advanced renal cell carcinoma initiated on first-line checkpoint inhibitor-based combination therapy.
First Author: Paul D. Nathan
Poster
2019 Genitourinary Cancers Symposium
Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.
First Author: David F. McDermott
Poster
2022 ASCO Annual Meeting
Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.
First Author: Lucia Carril-Ajuria